Interaction of RU 486, a glucocorticoid and progestin antagonist with human circulating mononuclear leukocytes

S. Kawai, D. D. Brandon, Donald (Lynn) Loriaux, G. P. Chrousos

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The glucocorticoid and progestin antagonist, RU 486 (17 β-hydroxy-11β-[4-dimethylaminophenyl]-17α-[1-propynyl]-estra-4, 9-dien-3-one), antagonizes the suppressive effect of dexamethasone on [14C]2-deoxyglucose uptake by intact human mononuclear leukocytes in a concentration-dependent fashion. The authors found at least two types of specific-binding sites for this compound in the mononuclear leukocytes. The first type of sites (receptor content [Ro], 10.8 ± 1.6 fmoles/106 cells [mean ± SD of 4 experiments]; equilibrium dissociation constant (Kd), 0.3 ± 0.1 nM) have a capacity similar to that of the dexamethasone binding site (Ro, 11.2 fmoles/106 cells; Kd, 1.2 nM). The second type of sites (Ro, 56 ± 27 fmoles/106 cells: Kd, 19 ± 5 nM) have a higher capacity and lower affinity for RU 486 than the first type of sites and do not interact with dexamethasone. The authors were unable to demonstrate the presence of the second type of binding sites in subcellular fractions. This finding suggests that site is unstable and lost in the fractionation process. The role of the second type of low-affinity, high-capacity RU 486 specific-binding site in intact human mononuclear leukocytes, as well as its possible occurrence in other tissue, requires further investigation.

Original languageEnglish (US)
Pages (from-to)167-171
Number of pages5
JournalAmerican Journal of the Medical Sciences
Volume298
Issue number3
StatePublished - 1989
Externally publishedYes

Fingerprint

Mononuclear Leukocytes
Mifepristone
Progestins
Glucocorticoids
Binding Sites
Dexamethasone
Subcellular Fractions
Deoxyglucose

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Interaction of RU 486, a glucocorticoid and progestin antagonist with human circulating mononuclear leukocytes. / Kawai, S.; Brandon, D. D.; Loriaux, Donald (Lynn); Chrousos, G. P.

In: American Journal of the Medical Sciences, Vol. 298, No. 3, 1989, p. 167-171.

Research output: Contribution to journalArticle

@article{3a26864204fe4d2882291796e72a527a,
title = "Interaction of RU 486, a glucocorticoid and progestin antagonist with human circulating mononuclear leukocytes",
abstract = "The glucocorticoid and progestin antagonist, RU 486 (17 β-hydroxy-11β-[4-dimethylaminophenyl]-17α-[1-propynyl]-estra-4, 9-dien-3-one), antagonizes the suppressive effect of dexamethasone on [14C]2-deoxyglucose uptake by intact human mononuclear leukocytes in a concentration-dependent fashion. The authors found at least two types of specific-binding sites for this compound in the mononuclear leukocytes. The first type of sites (receptor content [Ro], 10.8 ± 1.6 fmoles/106 cells [mean ± SD of 4 experiments]; equilibrium dissociation constant (Kd), 0.3 ± 0.1 nM) have a capacity similar to that of the dexamethasone binding site (Ro, 11.2 fmoles/106 cells; Kd, 1.2 nM). The second type of sites (Ro, 56 ± 27 fmoles/106 cells: Kd, 19 ± 5 nM) have a higher capacity and lower affinity for RU 486 than the first type of sites and do not interact with dexamethasone. The authors were unable to demonstrate the presence of the second type of binding sites in subcellular fractions. This finding suggests that site is unstable and lost in the fractionation process. The role of the second type of low-affinity, high-capacity RU 486 specific-binding site in intact human mononuclear leukocytes, as well as its possible occurrence in other tissue, requires further investigation.",
author = "S. Kawai and Brandon, {D. D.} and Loriaux, {Donald (Lynn)} and Chrousos, {G. P.}",
year = "1989",
language = "English (US)",
volume = "298",
pages = "167--171",
journal = "American Journal of the Medical Sciences",
issn = "0002-9629",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Interaction of RU 486, a glucocorticoid and progestin antagonist with human circulating mononuclear leukocytes

AU - Kawai, S.

AU - Brandon, D. D.

AU - Loriaux, Donald (Lynn)

AU - Chrousos, G. P.

PY - 1989

Y1 - 1989

N2 - The glucocorticoid and progestin antagonist, RU 486 (17 β-hydroxy-11β-[4-dimethylaminophenyl]-17α-[1-propynyl]-estra-4, 9-dien-3-one), antagonizes the suppressive effect of dexamethasone on [14C]2-deoxyglucose uptake by intact human mononuclear leukocytes in a concentration-dependent fashion. The authors found at least two types of specific-binding sites for this compound in the mononuclear leukocytes. The first type of sites (receptor content [Ro], 10.8 ± 1.6 fmoles/106 cells [mean ± SD of 4 experiments]; equilibrium dissociation constant (Kd), 0.3 ± 0.1 nM) have a capacity similar to that of the dexamethasone binding site (Ro, 11.2 fmoles/106 cells; Kd, 1.2 nM). The second type of sites (Ro, 56 ± 27 fmoles/106 cells: Kd, 19 ± 5 nM) have a higher capacity and lower affinity for RU 486 than the first type of sites and do not interact with dexamethasone. The authors were unable to demonstrate the presence of the second type of binding sites in subcellular fractions. This finding suggests that site is unstable and lost in the fractionation process. The role of the second type of low-affinity, high-capacity RU 486 specific-binding site in intact human mononuclear leukocytes, as well as its possible occurrence in other tissue, requires further investigation.

AB - The glucocorticoid and progestin antagonist, RU 486 (17 β-hydroxy-11β-[4-dimethylaminophenyl]-17α-[1-propynyl]-estra-4, 9-dien-3-one), antagonizes the suppressive effect of dexamethasone on [14C]2-deoxyglucose uptake by intact human mononuclear leukocytes in a concentration-dependent fashion. The authors found at least two types of specific-binding sites for this compound in the mononuclear leukocytes. The first type of sites (receptor content [Ro], 10.8 ± 1.6 fmoles/106 cells [mean ± SD of 4 experiments]; equilibrium dissociation constant (Kd), 0.3 ± 0.1 nM) have a capacity similar to that of the dexamethasone binding site (Ro, 11.2 fmoles/106 cells; Kd, 1.2 nM). The second type of sites (Ro, 56 ± 27 fmoles/106 cells: Kd, 19 ± 5 nM) have a higher capacity and lower affinity for RU 486 than the first type of sites and do not interact with dexamethasone. The authors were unable to demonstrate the presence of the second type of binding sites in subcellular fractions. This finding suggests that site is unstable and lost in the fractionation process. The role of the second type of low-affinity, high-capacity RU 486 specific-binding site in intact human mononuclear leukocytes, as well as its possible occurrence in other tissue, requires further investigation.

UR - http://www.scopus.com/inward/record.url?scp=0024445785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024445785&partnerID=8YFLogxK

M3 - Article

C2 - 2801752

AN - SCOPUS:0024445785

VL - 298

SP - 167

EP - 171

JO - American Journal of the Medical Sciences

JF - American Journal of the Medical Sciences

SN - 0002-9629

IS - 3

ER -